Tempest Therapeutics, Inc. (TPST): History, Ownership, Mission, How It Works & Makes Money

In the complex world of oncology therapeutics, is Tempest Therapeutics, Inc. (TPST) a company to watch? This clinical-stage biotechnology firm is making waves with its innovative approaches to cancer treatment, but what exactly does Tempest Therapeutics do, how did it get here, and how does it plan to make money? Delve into the history, ownership structure, and mission of this company, and explore the science behind its first-in-class therapeutics.

Tempest Therapeutics, a clinical-stage biotechnology company, is focused on developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. In 2024, Tempest Therapeutics reported a cash position of $30.3 million at year-end, with a net loss of $41.8 million. Keep reading to understand how Tempest Therapeutics is navigating the challenges and opportunities in the biotech landscape.

Tempest Therapeutics, Inc. (TPST) History

Tempest Therapeutics, Inc. Founding Timeline

Year established

Tempest Therapeutics was founded in 2011.

Original location

The company is headquartered in South San Francisco, California.

Founding team members

The founding team included:

• Tom Dubensky, Ph.D., who served as the President and Chief Executive Officer.
• Sam Saks was also a key part of the founding team.

Initial capital/funding

In 2012, Tempest Therapeutics completed a Series A financing round, raising $30 million. This funding was led by Versant Ventures with participation from Domain Associates.

Tempest Therapeutics, Inc. Evolution Milestones

Tempest Therapeutics, Inc. Transformative Moments

• Focus on TPST-1120 Development: A pivotal moment was the strategic decision to focus primarily on the development of TPST-1120, a selective PPARα antagonist. This decision channeled resources towards a promising asset with the potential to address significant unmet needs in oncology.
• Public Offering: The company's IPO provided a substantial influx of capital, enabling it to expand its research and development efforts, particularly in advancing TPST-1120 through clinical trials.
• Clinical Trial Progress: Progressing TPST-1120 into clinical trials marked a significant step, allowing the company to gather critical data on the drug's safety and efficacy in human subjects.
• Merger with Millendo Therapeutics: The merger with Millendo Therapeutics represented a transformative move to diversify the company's pipeline and explore new therapeutic areas beyond oncology, potentially mitigating risks and expanding opportunities.

Read more about Tempest Therapeutics in this related article: Exploring Tempest Therapeutics, Inc. (TPST) Investor Profile: Who’s Buying and Why?

Tempest Therapeutics, Inc. (TPST) Ownership Structure

Understanding Tempest Therapeutics, Inc.'s ownership structure provides insights into its governance and strategic direction. The company's ownership is distributed among various shareholders, including institutional investors, individual shareholders, and potentially company insiders.

Tempest Therapeutics, Inc.'s Current Status

Tempest Therapeutics is a public company, trading under the ticker symbol TPST. As a publicly traded entity, its shares are available for purchase by investors on the stock market.

Tempest Therapeutics, Inc.'s Ownership Breakdown

The ownership of Tempest Therapeutics is distributed among a mix of institutional and individual investors. While precise real-time data fluctuates, a recent snapshot of ownership is presented below.

Tempest Therapeutics, Inc.'s Leadership

The leadership team is responsible for the strategic direction and operational execution of Tempest Therapeutics. Key members of the leadership team include:

• Stephen Brady: President and Chief Executive Officer
• Sam Kleczka: Chief Financial Officer
• Dr. Zeenia Framroze: Chief Medical Officer

To gain more insight into the investors of Tempest Therapeutics, Inc., consider reading: Exploring Tempest Therapeutics, Inc. (TPST) Investor Profile: Who’s Buying and Why?

Tempest Therapeutics, Inc. (TPST) Mission and Values

Tempest Therapeutics is dedicated to developing innovative therapies that harness the power of the immune system to fight cancer. The company focuses on creating targeted treatments that can improve the lives of patients battling various forms of cancer.

Tempest Therapeutics' Core Purpose

Official mission statement

While an official, stand-alone mission statement is not readily available in the provided search results, Tempest Therapeutics' core purpose can be understood through its activities and focus:

• Developing first-in-class and best-in-class small molecule therapeutics that combine both direct tumor killing and immune-mediated mechanisms.
• Advancing novel oncology therapeutics to treat a wide range of tumors.
• Focusing on TPST-1120 (selective PPARα antagonist) and TPST-1495 (selective EP2/4 antagonist) as its primary drug candidates.

Vision statement

Similarly, a specific vision statement was not found in the search results. However, the vision of Tempest Therapeutics can be inferred from its goals and strategic direction:

• To become a leader in developing innovative cancer therapies.
• To significantly improve patient outcomes through novel therapeutic approaches.
• To create substantial value by addressing unmet needs in cancer treatment.

Company slogan/tagline

No specific company slogan or tagline was found in the provided search results. Investors can further explore Tempest Therapeutics' mission and values and a detailed analysis of their financial standing at Breaking Down Tempest Therapeutics, Inc. (TPST) Financial Health: Key Insights for Investors.

Tempest Therapeutics, Inc. (TPST) How It Works

Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing small molecule therapeutics that combine both direct tumor-killing and immune-mediated mechanisms to treat a wide range of cancers.

Tempest Therapeutics, Inc.’s Product/Service Portfolio

Tempest Therapeutics, Inc.’s Operational Framework

Tempest Therapeutics operates through a focused approach to drug development, concentrating on small molecule therapeutics that can modulate both tumor and immune responses. Their operational framework includes:

• Drug Discovery and Development: Identifying and developing small molecule candidates that target key pathways in cancer biology.
• Clinical Trials: Conducting rigorous Phase 1, Phase 2, and Phase 3 clinical trials to evaluate the safety and efficacy of their drug candidates.
• Partnerships and Collaborations: Collaborating with other pharmaceutical companies and research institutions to advance their drug development programs.
• Regulatory Affairs: Working closely with regulatory agencies like the FDA to secure drug approvals and bring their products to market.

The company's approach involves designing molecules that not only directly target tumor cells but also stimulate the immune system to recognize and eliminate cancer. This dual mechanism is intended to improve patient outcomes and overcome resistance to existing therapies.

Tempest Therapeutics, Inc.’s Strategic Advantages

Tempest Therapeutics distinguishes itself through several strategic advantages:

• Dual-Mechanism Approach: Their drugs are designed to both directly kill tumor cells and stimulate the immune system, offering a more comprehensive approach to cancer treatment.
• Targeted Therapies: By focusing on specific pathways and receptors, their therapies aim to minimize off-target effects and improve efficacy.
• Experienced Management Team: A team with a proven track record in drug development and commercialization guides the company.
• Strong Intellectual Property: Tempest Therapeutics maintains a robust patent portfolio to protect its drug candidates and technologies.

These advantages enable Tempest Therapeutics to potentially deliver more effective treatments for cancer patients and create value for its stakeholders. To gain more insights into the company's guiding principles, refer to Mission Statement, Vision, & Core Values of Tempest Therapeutics, Inc. (TPST).

Tempest Therapeutics, Inc. (TPST) How It Makes Money

Tempest Therapeutics, Inc. is a clinical-stage oncology company that primarily focuses on developing novel therapeutics that combine both targeted and immune-mediated mechanisms. As a company in the clinical stage, Tempest Therapeutics primarily makes money through strategic collaborations, licensing agreements, and potential future sales of its therapeutic products, contingent upon successful clinical trials and regulatory approvals.

[Company's] Revenue Breakdown

[Company's] Business Economics

Tempest Therapeutics operates under a business model common to biotechnology companies, characterized by high upfront research and development costs and the potential for substantial returns upon successful drug development and commercialization. Here are some key aspects of their business economics:

• R&D Investment: A significant portion of Tempest Therapeutics' expenditure is allocated to research and development. This includes preclinical studies, clinical trials, and other activities related to advancing their product candidates through the development pipeline.
• Partnerships and Licensing: Revenue generation relies heavily on establishing partnerships with larger pharmaceutical companies. These collaborations often involve upfront payments, milestone payments linked to clinical and regulatory achievements, and royalties on future product sales.
• Intellectual Property: The company's intellectual property portfolio is crucial for maintaining a competitive advantage. Strong patent protection helps secure market exclusivity for their therapeutic candidates, which is vital for attracting investment and partnership opportunities.
• Clinical Trial Expenses: Clinical trials represent a major cost driver. The expenses include patient enrollment, clinical site management, data analysis, and regulatory submissions. The progression of drug candidates through Phase 1, Phase 2, and Phase 3 trials escalates these costs significantly.
• Regulatory Approval: Achieving regulatory approval from agencies such as the FDA is a critical milestone. Successful approval not only validates the safety and efficacy of the drug but also unlocks the potential for commercial sales and revenue generation.

[Company's] Financial Performance

As a clinical-stage company, Tempest Therapeutics' financial performance is closely monitored for its cash runway, burn rate, and ability to secure additional funding to support ongoing research and development activities. Key aspects of their financial performance include:

• Cash Reserves: Monitoring the level of cash and cash equivalents is essential to ensure the company can fund its operations until it reaches a stage of sustainable revenue generation.
• Operating Expenses: Analyzing operating expenses, including R&D and general administrative costs, provides insights into the company's spending efficiency.
• Net Losses: Clinical-stage biotech companies typically incur net losses due to high R&D expenditures and the absence of product revenue. The magnitude of these losses and the company's ability to manage them are critical factors for investors.
• Financing Activities: Tempest Therapeutics relies on financing activities, such as equity offerings, debt financing, and strategic collaborations, to raise capital. The terms and conditions of these financing arrangements can significantly impact the company's financial health.

For more detailed insights into Tempest Therapeutics' financial health, you can explore further information here: Breaking Down Tempest Therapeutics, Inc. (TPST) Financial Health: Key Insights for Investors

Tempest Therapeutics, Inc. (TPST) Market Position & Future Outlook

Tempest Therapeutics is navigating a competitive landscape, aiming to solidify its position through strategic initiatives and targeted market opportunities, while also addressing potential risks that could impact its future performance. The company is dedicated to advancing transformative therapies with the potential to improve the lives of people with cancer.

Competitive Landscape

Opportunities & Challenges

Industry Position

Tempest Therapeutics is a biopharmaceutical company in the oncology space, focusing on developing therapies that modulate the tumor microenvironment and enhance immune response. Here are key aspects of its industry standing:

• Focus on Targeted Therapies: Tempest is concentrating on developing drugs that act on specific pathways involved in cancer progression.
• Clinical Stage Development: With key drug candidates in clinical trials, the company is working towards demonstrating efficacy and safety to gain regulatory approval.
• Partnerships and Collaborations: Strategic alliances could be vital for expanding capabilities and accelerating drug development.

To gain more insight into the company's core principles, explore: Mission Statement, Vision, & Core Values of Tempest Therapeutics, Inc. (TPST).